| Menopausal syndrome
Bijuva vs Lynkuet
Side-by-side clinical, coverage, and cost comparison for menopausal syndrome.Deep comparison between: Bijuva vs Lynkuet with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLynkuet has a higher rate of injection site reactions vs Bijuva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lynkuet but not Bijuva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bijuva
Lynkuet
At A Glance
Oral
Daily
Estrogen-progesterone combination
Oral
Daily
NK1/NK3 receptor antagonist
Indications
- Menopausal syndrome
- Menopausal syndrome
Dosing
Menopausal syndrome Start with 0.5 mg estradiol/100 mg progesterone orally once each evening with food; adjust dose based on clinical response; attempt to taper or discontinue at 3 to 6 month intervals.
Menopausal syndrome 120 mg (two 60 mg capsules) orally once daily at bedtime, with or without food; swallow capsules whole.
Contraindications
- Abnormal genital bleeding of unknown etiology
- Breast cancer or history of breast cancer
- Estrogen-dependent neoplasia
- Active deep vein thrombosis (DVT), pulmonary embolism (PE), or history of these conditions
- Active arterial thromboembolic disease (stroke, myocardial infarction) or history of these conditions
- Known anaphylactic reaction, angioedema, or hypersensitivity to BIJUVA
- Hepatic impairment or disease
- Known thrombophilic disorders, such as protein C, protein S, or antithrombin deficiency
- Pregnancy (exposure may cause pregnancy loss or stillbirth)
Adverse Reactions
Most common (>=3%) Breast tenderness, headache, nausea, vaginal bleeding, vaginal discharge, pelvic pain
Serious Cardiovascular disorders, malignant neoplasms
Postmarketing Abdominal pain, abdominal distention, diarrhea, vomiting, fatigue, malaise, weight increased, fluid retention, muscle spasms, pain in extremity, dizziness, somnolence, insomnia, sleep disorder, breast pain, uterine bleeding, night sweats, pruritus, hot flush
Most common (>=2%) headache, fatigue, dizziness, somnolence, abdominal pain, rash, diarrhea, muscle spasms
Serious CNS depressant effect and daytime impairment, hepatic transaminase elevations
Pharmacology
Estrogen-progesterone combination; estradiol binds nuclear estrogen receptors to reduce elevated gonadotropin levels and maintain secondary sexual characteristics in postmenopausal women, while progesterone binds progesterone receptors to transform proliferative endometrium into secretory endometrium and oppose estrogen actions.
Elinzanetant is an NK1 and NK3 receptor antagonist that inhibits Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, modulating neuronal activity in thermoregulation associated with hot flashes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bijuva
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (4/12)
Lynkuet
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (5/12)
UnitedHealthcare
Bijuva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lynkuet
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Bijuva
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Lynkuet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bijuva.
No savings programs available for Lynkuet.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BijuvaView full Bijuva profile
LynkuetView full Lynkuet profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.